Abrysvo from Pfizer Inc. - RSV vaccine pushes into pregnancy use

Reviewed: ad hoc news New Release & Launch desk. Edited and checked on 2026-06-24, 01:10. Details in the imprint.

Abrysvo from Pfizer Inc. enters the room as a quiet vial in a refrigerator drawer, but its target is loud: respiratory syncytial virus in older adults and pregnant women. Nurses describe the clear solution as almost "too ordinary" considering the stakes at birth wards.

What Abrysvo is

Abrysvo is a bivalent RSV vaccine based on the prefusion F protein, designed to prevent lower respiratory tract disease in adults aged 60 and above and in infants via maternal immunization. According to Pfizer's own materials, it uses stabilized F glycoprotein from RSV A and B subtypes.

The vaccine is supplied as a single-dose vial that is reconstituted and given intramuscularly, typically into the deltoid muscle. Pharmacist Sarah Klein, who trains staff in a US hospital network, calls the handling "straightforward" compared with some multi-dose or frozen biologics.

Regulatory green lights

The US Food and Drug Administration approved Abrysvo in May 2023 for adults aged 60 and older, after Phase 3 data showed significant efficacy against RSV-associated lower respiratory tract disease. In August 2023 the FDA extended approval for use during weeks 32 to 36 of pregnancy to protect newborns in their first six months.

European regulators followed: the European Commission granted marketing authorization for Abrysvo in adults and pregnant women later in 2023, enabling rollout across EU member states. Health authorities position it alongside other RSV vaccines, but with a distinctive maternal indication.

Dosing and protection window

For older adults, Abrysvo is administered as a single 0.5 ml intramuscular dose ahead of the RSV season, with no booster approved yet. In the RENOIR Phase 3 trial, this schedule cut the risk of RSV-associated lower respiratory tract disease with at least two symptoms by around two thirds.

In pregnancy, obstetrician Dr. María López explains that the timing window between 32 and 36 weeks is crucial: "You feel the clock," she says, as nurses line up the injection to maximize antibody transfer but avoid early delivery risks. Infants then benefit from maternal antibodies through the first RSV season.

How it compares

Abrysvo competes directly with GSK's Arexvy in older adults, but Pfizer's product has the specific maternal indication, which analysts see as a strategic differentiator. Pfizer highlights that its vaccine targets both RSV A and B strains using prefusion F protein, a design shared by the field's front-runners.

Public health agencies do not yet favor one RSV vaccine universally, instead offering options based on availability, pricing and local evidence. For investors, portfolio breadth across age groups and indications is what makes RSV a meaningful line item rather than a niche add-on.

Safety signals and limits

In clinical trials, common side effects included injection site pain, headache and fatigue, which trial investigator Dr. Edward Walsh described as "in line with other adult vaccines". Rare events such as preterm birth in the maternal trial led regulators to request ongoing surveillance.

Abrysvo is not intended for direct use in infants or young children outside the maternal program, and its role sits alongside monoclonal antibodies like nirsevimab, not instead of them. That layered approach shapes how hospitals build RSV prevention protocols each season.

Market rollout and stock context

Pfizer launched Abrysvo in the US for the 2023-24 RSV season and has been expanding access through pharmacies, hospitals and obstetric practices. Germany and other EU markets follow European Medicines Agency guidance, with reimbursement depending on national health systems.

Net-net, Abrysvo is one pillar in Pfizer's attempt to smooth revenue beyond its Covid peak, and Pfizer Inc shares (ISIN US7170811035) trade on the NYSE in US dollars, where RSV uptake joins oncology and immunology pipelines in investor models.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.